Low-risk identification in multiple myeloma using a new 14-gene model

Area of Science:

• Hematology
• Genomics
• Oncology

Background:

• Accurate prognostication is crucial for managing newly diagnosed multiple myeloma (MM).
• Identifying gene expression patterns associated with low-risk disease aids in treatment stratification.
• Existing models require further validation and comparison for optimal clinical utility.

Purpose of the Study:

• To develop and validate a novel gene expression signature for identifying low-risk multiple myeloma (MM).
• To compare the prognostic performance of the new model against established MM prognostic tools.
• To establish a reliable tool for predicting clinical outcomes in newly diagnosed MM patients.

Main Methods:

• Gene expression profiling (GEP) data from normal plasma cells, MM cell lines, MGUS, and newly diagnosed MM patients were analyzed.
• R/Bioconductor and siggenes packages were utilized for statistical analysis, including heatmap, boxplot, and histogram generation.
• Kaplan-Meier analysis and multivariate comparative analysis were employed for model validation and comparison with existing prognostic models.

Main Results:

• The MM Survival Index14 (MMSI14) comprising 14 genes was identified as a significant prognostic marker for low-risk MM.
• MMSI14 demonstrated superior prognostic value compared to other established models when applied to independent datasets.
• Low MMSI14 signature predicted longer survival, with 39% of patients classified as low-risk exhibiting >90% survival at 60 months.

Conclusions:

• MMSI14 is a novel and robust gene expression model for defining low-risk, newly diagnosed multiple myeloma (MM).
• The MMSI14 model provides the best available prognostic value for predicting clinical outcomes in MM patients.
• This model can aid in stratifying patients and guiding clinical treatment decisions for newly diagnosed MM.